Apogee Therapeutics Inc. (NASDAQ:APGE) Receives Average Recommendation of “Moderate Buy” from Brokerages

Shares of Apogee Therapeutics Inc. (NASDAQ:APGE) have been assigned an average recommendation of “Moderate Buy” from the twelve ratings firms that are covering the stock, Marketbeat Ratings reports. One research analyst has rated the stock with a sell rating, one has issued a hold rating, eight have issued a buy rating and two have assigned a strong buy rating to the company. The average twelve-month target price among analysts that have updated their coverage on the stock in the last year is $103.6364.

A number of research analysts recently weighed in on APGE shares. BTIG Research set a $137.00 target price on shares of Apogee Therapeutics in a report on Tuesday. Deutsche Bank Aktiengesellschaft started coverage on shares of Apogee Therapeutics in a report on Tuesday, December 9th. They issued a “buy” rating and a $103.00 target price on the stock. Stifel Nicolaus set a $133.00 target price on shares of Apogee Therapeutics in a research report on Tuesday. Mizuho began coverage on Apogee Therapeutics in a research report on Tuesday, October 21st. They issued an “outperform” rating and a $105.00 price target for the company. Finally, Stephens initiated coverage on Apogee Therapeutics in a research note on Tuesday, December 16th. They set an “overweight” rating and a $95.00 price objective on the stock.

Apogee Therapeutics Price Performance

Shares of APGE opened at $78.25 on Friday. The firm has a market cap of $5.35 billion, a P/E ratio of -17.87 and a beta of 1.41. The company has a 50 day simple moving average of $69.57 and a two-hundred day simple moving average of $51.22. Apogee Therapeutics has a 1 year low of $26.20 and a 1 year high of $80.99.

Apogee Therapeutics (NASDAQ:APGE) last released its quarterly earnings data on Monday, November 10th. The company reported ($1.11) EPS for the quarter, beating the consensus estimate of ($1.14) by $0.03. On average, sell-side analysts anticipate that Apogee Therapeutics will post -3.09 earnings per share for the current year.

Insider Activity at Apogee Therapeutics

In related news, insider Carl Dambkowski sold 10,900 shares of the stock in a transaction on Thursday, December 4th. The stock was sold at an average price of $75.00, for a total transaction of $817,500.00. Following the sale, the insider owned 271,108 shares in the company, valued at approximately $20,333,100. This represents a 3.87% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, CEO Michael Thomas Henderson sold 40,000 shares of Apogee Therapeutics stock in a transaction on Thursday, December 4th. The stock was sold at an average price of $75.01, for a total transaction of $3,000,400.00. Following the transaction, the chief executive officer directly owned 1,232,987 shares of the company’s stock, valued at $92,486,354.87. The trade was a 3.14% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last three months, insiders have sold 101,685 shares of company stock worth $7,179,630. Corporate insiders own 42.77% of the company’s stock.

Hedge Funds Weigh In On Apogee Therapeutics

Hedge funds have recently added to or reduced their stakes in the company. AlphaQuest LLC bought a new stake in Apogee Therapeutics in the first quarter worth about $43,000. Adage Capital Partners GP L.L.C. raised its holdings in shares of Apogee Therapeutics by 202.7% in the first quarter. Adage Capital Partners GP L.L.C. now owns 727,000 shares of the company’s stock worth $27,161,000 after buying an additional 486,800 shares during the period. Granahan Investment Management LLC lifted its stake in shares of Apogee Therapeutics by 16.7% during the 1st quarter. Granahan Investment Management LLC now owns 108,340 shares of the company’s stock worth $4,048,000 after acquiring an additional 15,486 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its stake in shares of Apogee Therapeutics by 2.9% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 24,529 shares of the company’s stock worth $921,000 after acquiring an additional 694 shares during the last quarter. Finally, Millennium Management LLC boosted its holdings in Apogee Therapeutics by 100.0% during the 1st quarter. Millennium Management LLC now owns 260,335 shares of the company’s stock valued at $9,726,000 after acquiring an additional 130,164 shares during the period. 79.04% of the stock is currently owned by institutional investors.

Apogee Therapeutics News Summary

Here are the key news stories impacting Apogee Therapeutics this week:

• Positive Sentiment: Interim Phase 1b results show rapid, durable suppression of FeNO through 16 weeks (and through 32 weeks for patients with follow-up), supporting potential 3- or 6-month dosing and reinforcing zumilokibart as a potential best‑in‑class anti‑IL‑13 candidate — a clear clinical-catalyst for valuation upside. Apogee Therapeutics Announces Positive Interim Results (GlobeNewswire)
• Positive Sentiment: Analyst upgrade: BTIG raised its price target on APGE to $128 with a Buy rating, giving a sizable upside scenario that can support further investor interest and higher valuations if follow-on data remains strong. APGE price target raised by BTIG (The Fly)
• Neutral Sentiment: Company hosted a conference call and management discussion / transcript is available — useful for detail on patient numbers, safety, durability, and planned next steps; investors should parse the transcript for sample size and endpoints before extrapolating commercial potential. Apogee Therapeutics Phase 1b results transcript (Seeking Alpha)
• Negative Sentiment: Mixed market reaction: some outlets reported that APGE stock fell after the asthma data was released — likely reflecting short‑term profit‑taking, investor caution about early‑stage biomarker data (sample size, clinical endpoints, safety, or commercial pathway), or expectations already priced in. Monitor follow-up detailed data and Q&A that address size and clinical relevance. Apogee Therapeutics stock falls after asthma trial data (Investing.com)

About Apogee Therapeutics

Apogee Therapeutics, Inc is a clinical-stage biotechnology company dedicated to the discovery and development of novel small molecule therapeutics that selectively target the nuclear receptor RORγt, a master regulator of T cell-driven inflammatory pathways. By modulating RORγt activity, Apogee aims to offer an oral treatment option for patients with autoimmune and inflammatory skin disorders.

The company’s lead candidate, APG-157, is an oral RORγt inverse agonist currently undergoing early-stage clinical evaluation for moderate to severe plaque psoriasis.